NeoGenomics

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NeoGenomics, Inc. (NEO)

Retrieved on: 
Tuesday, January 17, 2023
News, EBITDA, Office of Inspector General, U.S. Department of Health and Human Services, NGS, NEO, Human services, NeoGenomics, GPM, Defendant, Suite, Court, Fraud, Abuse, Tobacco, Pharmaceutical industry, Animal

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, NeoGenomics’ stock price fell $5.30, or 29.8%, to close at $12.49 per share on March 29, 2022, thereby injuring investors further.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

NEOGENOMICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NeoGenomics, Inc. - NEO

Retrieved on: 
Wednesday, January 11, 2023
NeoGenomics, KSF, District court, Court, Health insurance, Private investigator

NEW ORLEANS, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 6, 2023 to file lead plaintiff applications in a securities class action lawsuit against NeoGenomics, Inc. (NasdaqCM: NEO), if they purchased the Company’s securities between February 27, 2020 and April 26, 2022, inclusive (the “Class Period”).

Key Points: 
  • NEW ORLEANS, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 6, 2023 to file lead plaintiff applications in a securities class action lawsuit against NeoGenomics, Inc. (NasdaqCM: NEO), if they purchased the Company’s securities between February 27, 2020 and April 26, 2022, inclusive (the “Class Period”).
  • This action is pending in the United States District Court for the Southern District of New York.
  • If you purchased securities of NeoGenomics and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqcm-neo/ to learn more.
  • If you wish to serve as a lead plaintiff in this class action, you must petition the Court by February 6, 2023.

DEADLINE ALERT for GNRC, GPS, VERU, and NEO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Wednesday, January 11, 2023
NGS, EUA, Law, NeoGenomics, Marcus Annius Verus Caesar, Defendant, Suite, Generac Holdings, Complaint, Fraud, Abuse, Investment, Mail, Holding company, Risk management

LOS ANGELES, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles

DEADLINE ALERT for GPS, VERU, NEO, SI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Tuesday, January 10, 2023
NGS, EUA, Law, Class, NeoGenomics, Telephone, Suite, Old Navy, Fraud, Abuse, Investment, People's Law Office, Security (finance), Risk management

BENSALEM, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

ROSEN, A LONGSTANDING LAW FIRM, Encourages NeoGenomics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NEO

Retrieved on: 
Tuesday, January 10, 2023
Titan, NeoGenomics, NGS, NEO, Advertising, Class, Court, I-Space (Chinese company), Fraud, Tobacco, Insurance

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.

Key Points: 
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

NEOGENOMICS, INC. (NASDAQ: NEO) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NeoGenomics, Inc. (NASDAQ: NEO)

Retrieved on: 
Tuesday, January 10, 2023
News, Hospital, EBITDA, Marie Cassidy, Office of Inspector General, U.S. Department of Health and Human Services, NGS, District court, NEO, Human services, Labour government, Court, Cancer, Complaint, Fraud, Advertising, Investment, The Legal 500, Tobacco, Pharmaceutical industry, Security (finance), NeoGenomics

NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) between February 27, 2020 and April 26, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

GPS, NEO & NBEV Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

Retrieved on: 
Tuesday, January 10, 2023
Marie Cassidy, Complaint, Navy, Risk, NeoGenomics, Newage, Office of Federal Contract Compliance Programs, Cancer, Court, Old Navy, Fraud, Tobacco

You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq.

Key Points: 
  • You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • If you suffered a loss, you can request that the Court appoint you as lead plaintiff.
  • Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NeoGenomics, Inc. (NEO) Class Action Notice: Contact Robbins LLP for Information Regarding the Class Action Against NeoGenomics, Inc.

Retrieved on: 
Monday, January 9, 2023
Complaint, NeoGenomics, Ability, Fraud, Hospital, Quality, NEO, Marie Cassidy, NGS, Pharmaceutical industry

NeoGenomics provides cancer tests and testing services to doctors, clinics, hospitals, and pharmaceutical companies.

Key Points: 
  • NeoGenomics provides cancer tests and testing services to doctors, clinics, hospitals, and pharmaceutical companies.
  • Among the Company’s portfolio of tests are next generation sequencing (“NGS”) tests.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against NeoGenomics, Shareholders who want to act as lead plaintiff for the class must file their papers by February 6, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO

Retrieved on: 
Monday, January 9, 2023
News, EBITDA, Office of Inspector General, U.S. Department of Health and Human Services, Human services, NeoGenomics, LLP, Pomerantz, Pharmaceutical industry

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO).

Key Points: 
  • NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether NeoGenomics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against F45 Training, Silvergate, NeoGenomics, and Iris and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, January 9, 2023
News, Form, Registration statement, Hospital, Register, Person, Class, Office of Inspector General, U.S. Department of Health and Human Services, NeoGenomics, Defendant, Growth, Cancer, Marie Cassidy, FTX, Workforce, Prospectus, U.S. Department of Defense Strategy for Operating in Cyberspace, NGS, Bear's Cave (Erpfingen), Bears' Cave, NYSE, Adjustment, Office of Federal Contract Compliance Programs, Silvergate Media, P.C, Exercise, Nonrecourse debt, EBITDA, Failure, F45, COVID-19, NEO, IPO, Human services, Complaint, Fraud, Security (finance), Property management, Video game, Renewable energy, Pharmaceutical industry, Cryptocurrency, Risk management, Audit, Bitcoin, Iris

For more information on the F45 Training class action go to: https://bespc.com/cases/FXLV

Key Points: 
  • For more information on the F45 Training class action go to: https://bespc.com/cases/FXLV
    Silvergate is a digital currency company.
  • Its platform, the Silvergate Exchange Network (“SEN”), provides payments, lending, and funding solutions for an expanding class of digital currency companies and investors.
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • As of the time this Complaint was filed, Iris’s ordinary shares continue to trade significantly below the $28 per share Offering price, damaging investors.